Logo

ALGS

Aligos Therapeutics, Inc.

ALGS

Aligos Therapeutics, Inc. • NASDAQ
$9.58 ▼ -2.84% (-0.28)
Market Cap $58.95 M
52w High $46.80
52w Low $3.76
Dividend Yield 0%
P/E -0.71
Volume 26.94K
Outstanding Shares 6.15M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $741K ▼ $29.102M ▲ $-31.537M ▼ -4.256K% ▼ $-3.04 ▼ $-30.783M ▼
Q2-2025 $965K ▲ $19.273M ▼ $-15.863M ▼ -1.644K% ▼ $-1.53 ▼ $-15.419M ▲
Q1-2025 $311K ▼ $19.554M ▼ $43.088M ▲ 13.855K% ▲ $5.12 ▲ $-18.733M ▲
Q4-2024 $629K ▼ $21.192M ▼ $-82.15M ▼ -13.06K% ▼ $-13.08 ▼ $-19.892M ▼
Q3-2024 $1.269M $21.4M $-19.259M -1.518K% $-3.07 $-19.464M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $99.096M ▼ $109.764M ▼ $37.931M ▲ $71.833M ▼
Q2-2025 $122.945M ▼ $134.706M ▼ $32.84M ▼ $101.866M ▼
Q1-2025 $137.861M ▲ $150.699M ▲ $34.254M ▼ $116.445M ▲
Q4-2024 $56.939M ▼ $70.094M ▼ $99.067M ▲ $-28.973M ▼
Q3-2024 $74.922M $88.426M $38.33M $50.096M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-31.537M ▼ $-24.345M ▼ $47.683M ▲ $-53K ▲ $23.285M ▲ $-24.538M ▼
Q2-2025 $-15.863M ▼ $-15.504M ▲ $-39.421M ▲ $-177K ▼ $-55.102M ▼ $-15.613M ▲
Q1-2025 $43.088M ▲ $-20.909M ▼ $-44.067M ▼ $101.742M ▲ $36.766M ▲ $-20.952M ▼
Q4-2024 $-82.15M ▼ $-18.403M ▲ $19.972M ▲ $97K ▲ $1.666M ▲ $-18.431M ▲
Q3-2024 $-19.259M $-20.101M $10.398M $-4K $-9.707M $-20.127M

Five-Year Company Overview

Income Statement

Income Statement Aligos is still a classic clinical‑stage biotech story: almost no product revenue and recurring operating losses. The company’s costs to run research, clinical trials, and the organization far exceed its tiny collaboration income, so it has reported losses every year shown. The loss level has been fairly steady in absolute terms, reflecting an ongoing but not dramatically expanding cost base. The very large swing in earnings per share in the latest year mainly reflects the reverse stock split, not a sudden change in the underlying business. Overall, the income statement shows a company firmly in the investment phase of drug development, with no sign yet of commercial-scale revenue to offset expenses.

Balance Sheet

Balance Sheet The balance sheet has been weakening over time. Cash and total assets have stepped down from earlier years, suggesting the company has been using its cash reserves to fund operations without fully replacing them. Debt remains small, so the capital structure is not heavily leveraged, but shareholder equity has moved from clearly positive to negative in the most recent year. That shift into negative equity signals that accumulated losses now exceed the capital invested and retained, which is common for small biotechs but still an important risk flag. In practical terms, the balance sheet points to a company increasingly dependent on future fundraising, partnerships, or other external support.

Cash Flow

Cash Flow Cash flow patterns underline the same theme: steady cash burn, no offsetting cash inflows from a commercial product, and essentially no spending on long‑term physical assets. Operating cash outflows have been fairly consistent year after year, which suggests disciplined but ongoing R&D and corporate spending. Free cash flow is negative and closely tracks operating cash flow, meaning the main drain on cash is running the business and funding research, not capital projects. Without new capital, this burn will keep eroding the cash balance, so the company’s future flexibility rests heavily on its ability to raise funds or bring in partners at acceptable terms.

Competitive Edge

Competitive Edge Aligos is trying to carve out a position in areas of significant unmet medical need, especially chronic hepatitis B and MASH. These are large, attractive markets, but they are also highly competitive, with many well‑funded players and big pharmaceutical companies working on similar targets. Aligos’ edge is its focus on “best‑in‑class” small molecules, a management team with deep experience in liver and viral diseases, and drug candidates designed to be more potent, more selective, or more convenient than rivals. On the other hand, as a small, loss‑making company with limited resources and no approved products, it is at a structural disadvantage on scale, marketing, and trial funding, and is likely to rely on partnerships to fully compete.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Aligos’ story. Its lead hepatitis B candidate aims to attack the virus in more than one way, targeting both replication and the viral reservoir in liver cells, which could support deeper and more durable responses if the data hold up. Its MASH drug is built around a liver‑focused receptor with high selectivity, aiming to reduce liver fat meaningfully while limiting off‑target side effects. Early and mid‑stage trial results have been encouraging but are far from conclusive, and timelines extend over several years. The pipeline also includes an early pan‑coronavirus protease inhibitor, which is promising conceptually but still at a formative stage. Overall, the R&D portfolio is focused and scientifically sophisticated, yet success will depend on future trial results and the ability to secure development partners.

Summary

Aligos is an early‑stage, research‑driven biotech with an ambitious pipeline but a financially fragile profile. On the scientific side, it is pursuing differentiated, potentially best‑in‑class therapies in large liver and viral disease markets, supported by an experienced team and initial clinical data that justify continued development. On the financial side, it has minimal revenue, persistent losses, shrinking cash reserves, and now negative equity, all of which highlight a heavy reliance on new capital or partnering deals. The reverse stock split is mostly a cosmetic capital markets move but underscores the company’s dependence on investor support. Overall, Aligos represents a typical high‑risk, high‑uncertainty biotech trajectory: meaningful upside if its drugs progress successfully, but significant financing and execution risks along the way.

NEWS

November 14, 2025 · 8:00 AM UTC

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 10, 2025 · 8:00 AM UTC

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Read more

November 6, 2025 · 8:30 AM UTC

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 8:30 AM UTC

Aligos Therapeutics to Present at Upcoming Investor Conferences

Read more

October 30, 2025 · 8:30 AM UTC

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Read more